Summary & Overview
CPT 78815: PET/CT Tumor Imaging, Skull Base to Mid‑Thigh
Headline: PET/CT Skull Base to Mid‑Thigh (CPT 78815) Remains a Central Tool in Oncologic Staging
Lead: CPT 78815 denotes PET imaging with concurrently acquired CT from the skull base to mid‑thigh, a widely used diagnostic nuclear medicine procedure for whole‑body oncologic evaluation. The code captures combined metabolic and anatomic imaging that informs staging, treatment planning, and response assessment across multiple cancer types.
Why it matters: This comprehensive PET/CT exam is central in cancer care pathways because it images a broad anatomic range commonly involved in metastatic disease. National payers routinely adjudicate claims for this service, and coverage policies shape access to PET/CT for staging, restaging, and therapy monitoring.
Payers covered: Analysis includes major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication outlines the clinical scope of CPT 78815, how it differs from limited and whole‑body PET/CT codes, typical sites of service, common billing modifiers, and relevant clinical indications tied to oncologic diagnoses. Readers will find benchmarking context for utilization and billing practice, an overview of payer coverage patterns and policy considerations, and operational notes for coding and claim submission. It also highlights areas where guidance or clarification is commonly needed and notes where input was not available.
Scope note: Content is national in focus and designed for coding, billing, and clinical stakeholders seeking concise policy and operational context for CPT 78815.
CPT Code Overview
CPT 78815 describes tumor imaging using positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization, covering the region from the skull base to mid‑thigh. This procedure is categorized under Diagnostic Nuclear Medicine Procedures and provides metabolic and anatomic imaging in a single session to evaluate malignant disease extent and activity.
The typical site of service for CPT 78815 is Outpatient Hospital (POS 22).
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical outpatient presents for tumor imaging with PET/CT for oncologic staging or restaging. The referring medical oncologist or surgical oncologist orders a 78815 study to evaluate disease extent from skull base to mid‑thigh after diagnosis or for treatment response assessment. The patient arrives to the outpatient hospital radiology department (POS 22); a nuclear medicine technologist verifies identity, reviews recent glucose values if FDG PET is used, administers radiotracer, and allows uptake time. A PET acquisition is performed with a concurrently acquired CT for attenuation correction and anatomical localization from the skull base through mid‑thigh. A nuclear medicine physician interprets images, documents findings, and provides a report to the referring clinician. Billing may separate professional and technical components using modifiers as appropriate.
Coding Specifications
Modifier 26 (Professional Component):
- Used when billing only the physician interpretation and report for the
78815service.
Modifier TC (Technical Component):
- Used when billing only the imaging equipment, technologist services, and image acquisition for the
78815service.
Modifier 59 (Distinct Procedural Service):
- Used when the
78815procedure is distinct and separate from other procedures performed on the same day; indicates a separate encounter or service.
Associated provider taxonomies and specialties:
| Taxonomy Code | Specialty Name |
|---|---|
2085R0202X | Radiology, Diagnostic Radiology |
2085N0700X | Radiology, Nuclear Radiology |
207U00000X | Nuclear Medicine Physician |
Related Diagnoses
-
C34.90— Malignant neoplasm of unspecified part of unspecified bronchus or lung- Relevance: Lung malignancy is a common indication for whole‑body or skull base to mid‑thigh PET/CT for staging, detection of metastases, and treatment response assessment.
-
C50.919— Malignant neoplasm of unspecified site of unspecified female breast- Relevance: Breast cancer patients may undergo PET/CT to evaluate metastatic disease or recurrence when systemic staging beyond regional imaging is needed.
-
C61— Malignant neoplasm of prostate- Relevance: Prostate cancer can be evaluated with PET/CT in certain settings for staging or assessment of metastatic spread; PET/CT coverage from skull base to mid‑thigh can detect common metastatic sites.
-
C18.9— Malignant neoplasm of colon, unspecified- Relevance: Colon cancer staging or restaging may use PET/CT to identify metastatic disease in the chest, abdomen, and pelvis within the skull base to mid‑thigh field.
-
C25.9— Malignant neoplasm of pancreas, unspecified- Relevance: Pancreatic malignancies may be evaluated with PET/CT for detection of metastatic disease and to guide management when whole‑body or skull base to mid‑thigh imaging is appropriate.
Related CPT Codes
| CPT Code | Description |
|---|---|
78814 | Tumor imaging, PET with concurrently acquired CT for attenuation correction and anatomical localization; limited area (eg, chest, head/neck) |
78816 | Tumor imaging, PET with concurrently acquired CT for attenuation correction and anatomical localization; whole body |
Relationship to 78815 in clinical workflow:
-
78814is a limited-area PET/CT (for example, chest or head/neck) and may be used instead of78815when imaging is restricted to a regional area rather than skull base to mid‑thigh. -
78816denotes whole body tumor PET/CT and represents a broader acquisition than78815; selection depends on clinical indication and required anatomic coverage. -
78814and78816are alternatives to78815based on the anatomic extent required.78815covers skull base to mid‑thigh and may be used in workflows where that specific coverage is indicated. -
These codes are commonly considered together when determining the appropriate PET/CT extent; billing usually includes only the single CPT code that matches the anatomic coverage performed.
National Reimbursement Benchmarks
Medicare mean allowed rate is substantially lower than the BUCA national commercial average, with Medicare at $112.28 versus BUCA at $1,106.03 for CPT 78815. This reflects the large gap between government reimbursement and commercial payer averages.
Rate dispersion (P75 minus P25) varies notably across payers. UnitedHealth Group shows the widest interquartile spread (approximately $775.40), followed by Blue Cross Blue Shield (about $725.00) and BUCA (about $502.68). Medicare is the tightest (about $6.00), indicating very low variability across localities. The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.